House Member Presses DOJ on Cannabis Rescheduling Timeline
Congressional pressure mounts on Justice Department for progress update on marijuana reclassification, three months after Trump administration directive.
Congressional oversight of federal cannabis policy intensifies as a House member formally requests an update from the Department of Justice regarding marijuana rescheduling progress. The inquiry comes three months after the Trump administration issued an executive order directing federal agencies to review cannabis classification under the Controlled Substances Act.
The timing of this congressional intervention reflects growing impatience with the pace of federal cannabis reform. Industry stakeholders have watched closely as the DOJ navigates the complex regulatory framework surrounding marijuana's Schedule I status, which currently places cannabis alongside heroin and LSD as substances with no accepted medical use.
This congressional pressure could accelerate the rescheduling timeline, potentially moving cannabis to Schedule III alongside substances like ketamine and testosterone. Such a change would eliminate the 280E tax burden that has constrained cannabis operators' profitability for years, allowing companies to deduct standard business expenses. Multi-state operators like Curaleaf, Green Thumb Industries, and Cresco Labs would see immediate margin improvements from tax relief.
The cannabis sector trades heavily on federal policy developments, with rescheduling representing the most significant regulatory catalyst since state-level legalization began. Current market valuations reflect deep discounts due to federal prohibition, limited banking access, and punitive tax treatment. A Schedule III designation would address two of these three core issues while maintaining federal oversight.
Congressional involvement signals that cannabis rescheduling remains a bipartisan priority despite political transitions. The industry's institutional investment thesis depends largely on federal normalization, making regulatory progress essential for sustained capital formation and market maturation. This latest development maintains momentum toward federal cannabis reform, even as implementation timelines remain uncertain.